Skip to main content
. 2019 Aug 14;14(3):357–367. doi: 10.5009/gnl18269

Table 6.

Characteristics of Patients with G3-HCV Cirrhosis Who Showed no Response to Past and Current Antiviral Treatments

Patient Age, yr/sex Past treatment HCV RNA >800,000 IU/mL CPT class Treatment NS5A/NS5B resistance test, posttreatment
1 50/M Relapsed after PegIFN/RBV No A DCV/SOF/RBV 1,000 mg Not performed
2 56/F None Yes A DCV/SOF Y93H
3 52/M Relapsed after PegIFN/RBV No A DCV/SOF Y93H
4 50/M None No B DCV/SOF Y93H
5 60/M No response to PegIFN/RBV Yes A DCV/SOF Y93H
6 52/M No response to PegIFN/RBV No A DCV/SOF/RBV 1,000 mg Y93H-L159F- L31M
7 52/M Relapsed after SOF/RBV No A DCV/SOF Y93H
8 48/F None No B DCV/SOF Y93H
9 46/M None Yes B DCV/SOF/RBV 800 mg Y93H
10 41/M None No B DCV/SOF Y93H
11 57/M No response to PegIFN/RBV Yes A DCV/SOF Y93H
12 61/M Relapsed after PegIFN/RBV Yes A DCV/SOF None

G3-HCV, genotype 3 hepatitis C virus; CPT, Child-Pugh-Turcotte; M, male; F, female; PegIFN, pegylated interferon; RBV, ribavirin; DCV, daclatasvir; SOF, sofosbuvir.